Newsletter

Akebia Reports Successful Clinical Trial Results

On September 26, Akebia Therapeutics (AKBA) reported positive results from a phase 2 clinical trial of the drug Vadadustat. The study results came from Japanese patients with anemia associated with non-dialysis chronic kidney disease and confirmed prior findings.   Rocket Tickers detected the event and sent out an alert at 7:00 am. The next trade […]

0Comments

ZGNX Climbs on Clinical Trial Results

On September 29, Zogenix (ZGNX) reported positive results from its phase 3 clinical trial for the drug ZX008. The drug treats a rare form of epilepsy known as Dravet Syndrome.   Rocket Tickers caught the news at 7:00 am and sent out a level 2 alert. The stock price immediately surged but then faded after […]

0Comments

Alnylam Pharmaceuticals Reports Clinical Trial Success

On September 20, Alnylam Pharmaceuticals (ALNY) reported exciting stage 3 clinical trial results. Its drug, patisiran, treats a rare nerve disorder called familial amyloid polyneuropathy. Alnylam will seek regulatory approval for patisiran later this year. Rocket Tickers sent out a level 2 alert at 7 am, and the next trade was at $93.50. The price […]

0Comments

LCI Receives FDA Approval for New Drug

Lannett Company (LCI) announced on September 27 that is had received FDA approval for a new drug. The Oxycodone and Acetaminophin tablets USP, 5 mg/325 mg and 10 mg/325 mg are the therapeutic equivalent to the drug Percocet. U.S. sales of Oxycodone and Acetaminophin tablets USP, 5 mg/325 mg and 10 mg/325 mg totaled around […]

0Comments

Latest of Knowledge Center